AKT1 and cancer: To date, the strongest rationale exists for combining metformin with everolimus, which could synergize at a molecular (i.e., by strengthening inhibition of the PI3K/AKT/mTOR pathway and inhibiting cancer cell anabolism) and systemic (i.e., by reducing blood glucose, triglyceride, and cholesterol concentration) levels.